Capricor Therapeutics (CAPR) News Today $10.48 +0.23 (+2.24%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$10.52 +0.04 (+0.43%) As of 05/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $35.50 Consensus Target Price from AnalystsMay 28 at 2:07 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 26 at 10:00 AM | prnewswire.comD. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR)D. E. Shaw & Co. Inc. purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 53,734 shares of the biotechnology company's stMay 26 at 3:34 AM | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of "Buy" by AnalystsShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objectiMay 26 at 3:07 AM | marketbeat.comWoodline Partners LP Invests $8.69 Million in Capricor Therapeutics Inc (NASDAQ:CAPR)Woodline Partners LP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 629,934 shares of the biotechnology company's stMay 25 at 4:41 AM | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Cut to "Sell" at Wall Street ZenWall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday.May 24, 2025 | marketbeat.comResearch Analysts Issue Forecasts for CAPR Q2 EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Stock analysts at Roth Capital issued their Q2 2025 EPS estimates for Capricor Therapeutics in a research report issued to clients and investors on Tuesday, May 20th. Roth Capital analyst B. Pachaiyappan expects that the biotechnology companMay 24, 2025 | marketbeat.comWall Street Zen Downgrades Capricor Therapeutics (NASDAQ:CAPR) to SellMay 24, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for CAPR Q2 EarningsMay 24, 2025 | americanbankingnews.comFY2026 Earnings Estimate for CAPR Issued By Roth CapitalCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at Roth Capital issued their FY2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Tuesday, May 20th. Roth Capital analyst B. Pachaiyappan expects that the biotechnology compaMay 23, 2025 | marketbeat.com126,311 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Rafferty Asset Management LLCRafferty Asset Management LLC bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 126,311 shares of the biotechnology companMay 23, 2025 | marketbeat.comNorthern Trust Corp Boosts Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)Northern Trust Corp increased its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 43.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 384,157 shares of the biotechnology company's stock after buying an additional 116,086May 23, 2025 | marketbeat.comCapricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA DateMay 23, 2025 | seekingalpha.comCapricor Therapeutics (NASDAQ:CAPR) Coverage Initiated by Analysts at Roth CapitalMay 23, 2025 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Now Covered by Analysts at Roth CapitalRoth Capital began coverage on Capricor Therapeutics in a research report on Tuesday. They set a "buy" rating and a $31.00 target price on the stock.May 22, 2025 | marketbeat.comUncertainties Regarding Capricor's CAP-1002 ApprovalMay 22, 2025 | seekingalpha.comWhat is Roth Capital's Estimate for CAPR FY2026 Earnings?May 22, 2025 | americanbankingnews.comCapricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside PotentialMay 22, 2025 | msn.comCapricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA DecisionMay 22, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 20, 2025 | prnewswire.comCAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 20, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 18, 2025 | globenewswire.comFY2025 EPS Estimates for CAPR Raised by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comCAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMay 16, 2025 | businesswire.comAnalysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest ResultsMay 16, 2025 | finance.yahoo.comMaven Securities LTD Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR)Maven Securities LTD bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 150,000 shares of the biotechnology company'sMay 15, 2025 | marketbeat.comCapricor Therapeutics appoints new Chief Medical OfficerMay 14, 2025 | investing.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comCapricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...May 14, 2025 | gurufocus.comQ1 2025 Capricor Therapeutics Inc Earnings Call TranscriptMay 14, 2025 | gurufocus.comCapricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call TranscriptMay 13, 2025 | seekingalpha.comCapricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparationsMay 13, 2025 | msn.comCapricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | finance.yahoo.comCapricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical OfficerMay 13, 2025 | finance.yahoo.comCapricor Therapeutics, Inc. Q1 2025 Earnings PreviewMay 13, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 12, 2025 | prnewswire.comWhat To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 EarningsMay 12, 2025 | gurufocus.com2,250,400 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Bought by Farallon Capital Management LLCFarallon Capital Management LLC bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,250,400 shares of the biotechnology company's stock,May 11, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRMay 9, 2025 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth PlansMay 7, 2025 | finance.yahoo.comCapricor Therapeutics (CAPR) Projected to Post Quarterly Earnings on MondayCapricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-capricor-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comFreestone Grove Partners LP Buys New Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)Freestone Grove Partners LP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 22,920 shares of the biotechnology company's stock, valued atMay 7, 2025 | marketbeat.comBarclays PLC Has $1.24 Million Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)Barclays PLC increased its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 147.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,650 shares of the biotechnology company's stock after acMay 7, 2025 | marketbeat.comCapricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13May 6, 2025 | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co.JPMorgan Chase & Co. decreased its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 70.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,680 shares of the biotechnology company's stock after selling 39,519May 6, 2025 | marketbeat.comCapricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s OptimisticMay 5, 2025 | msn.comUS FDA to convene expert panel for Capricor Therapeutics' DMD cell therapyMay 5, 2025 | reuters.comCapricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyMay 5, 2025 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - Time to Sell?May 5, 2025 | marketbeat.com59,303 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 59,303 shares of the biotechnology company's stockMay 3, 2025 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.681.03▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼255▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SUPN News Today AGIO News Today CNTA News Today EVO News Today ARQT News Today IDYA News Today IRON News Today BHC News Today BHVN News Today SDGR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CAPR Stock Free CAPR Stock Alerts